Invested in Sustainable Value Creation

Wavelength’s Operating Executives specialize in the
nexus of Lifesciences, Healthcare, and Technology.

We focus on delivering sustainable value...
not on account development.

Expertise Bound With Long Term Perspective

Wavelength’s Operating Executives specialize in the nexus of Lifesciences, Healthcare, and Technology. We deliver transformations resulting in sustainable business value.

We solve complex problems with small teams possessing deep industry expertise. Rolling up our sleeves, we get our hands dirty and work quickly to distill and resolve your needs - driven by an energy and passion for great results. You can count on us to introduce fresh, sound ideas tempered by an experience-tested dose of realism. We always align with our business partners through shared interests.

Our approach will be most refreshing if you’ve ever been oversupplied with high dollar, marginal talent, sold work that didn’t move the needle on the business, or received a strategic plan filled with bright, but flawed and non-implementable ideas.

We’ve held many roles - executives, entrepreneurs, and consultants. These experiences mean we have seen numerous scenarios from multiple viewpoints. You will never have to question our loyalty. When you partner with us, it’s your agenda, period.

If all this resonates with you, then we are

... on your Wavelength

Global News in Lifesciences, Healthcare, and Technology

World's First FDA IDE Coronary Patient Treated With a DEB

NYON, Switzerland, July 10, 2020 -- (Healthcare Sales & Marketing Network) -- MedAlliance has announced enrollment of the first patient in its study of SELUTION SLR™ 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted b...
Devices, Interventional, Cardiology
MedAlliance, SELUTION SLR, Sirolimus, Drug Eluting Balloon

Comcast xFi Advanced Gateway Modem/Router

Here is Comcast?s most advanced modem/router which promises speed as well as ease of use.

Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study

STOCKHOLM, July 10, 2020 -- (Healthcare Sales & Marketing Network) -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a positive top line result for the company's pivotal phase III study, IsoConDa. The study reached its primary endpoint; t...
Biopharmaceuticals
Sedana Medical, IsoConDa , isoflurane, inhaled sedation

Harman Kardon ? Home Speaker with Cortana

Here is a premium home speaker with superior sound coupled with Microsoft?s Cortana